Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial

Keyphrases

• Heart Failure with Preserved Ejection Fraction (HFpEF) 100%
• Spironolactone 100%
• Sex Differences 100%
• TOPCAT Trial 100%
• All-cause Mortality 37%
• TOPCAT 37%
• HF Hospitalization 25%
• Hazard Ratio 12%
• Clinical Outcomes 12%
• Placebo 12%
• Comorbidity 12%
• Heart Failure 12%
• Left Ventricular Ejection Fraction 12%
• Cardiac Arrest 12%
• Treatment Effect 12%
• Patients with Heart Failure 12%
• Cardiovascular Hospitalizations 12%
• Mineralocorticoid Receptor Antagonists 12%
• Cardiovascular Mortality 12%
• Prospective Evaluation 12%
• Patient-reported Outcomes 12%
• Heart Failure Treatment 12%
• Time-to-event Analysis 12%
• Clinical Profile 12%
• Aldosterone Antagonists 12%
• Non-cardiovascular 12%
• Outcome Effect 12%
• Placebo Treatment 12%
• Non-cardiovascular Mortality 12%
• Preserved Systolic Function 12%

Biochemistry, Genetics and Molecular Biology

• Heart Ejection Fraction 100%
• Sex Difference 100%
• Spironolactone 100%
• All Cause Mortality 37%
• Heart Left Ventricle Ejection Fraction 12%
• Cardiovascular Mortality 12%
• Cardiac Arrest 12%
• Mineralocorticoid 12%
• Comorbidity 12%
• Aldosterone 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Spironolactone 100%
• Heart Failure with Preserved Ejection Fraction 100%
• All Cause Mortality 37%
• Placebo 25%
• Congestive Heart Failure 12%
• Heart Arrest 12%
• Mineralocorticoid Antagonist 12%
• Cardiovascular Mortality 12%
• Aldosterone Antagonist 12%
• Comorbidity 12%